| Literature DB >> 33925233 |
Alessia Vignoli1,2, Emanuela Risi3, Amelia McCartney3,4, Ilenia Migliaccio3, Erica Moretti3, Luca Malorni3, Claudio Luchinat1,2,5, Laura Biganzoli3, Leonardo Tenori1,2,5.
Abstract
Precision oncology is an emerging approach in cancer care. It aims at selecting the optimal therapy for the right patient by considering each patient's unique disease and individual health status. In the last years, it has become evident that breast cancer is an extremely heterogeneous disease, and therefore, patients need to be appropriately stratified to maximize survival and quality of life. Gene-expression tools have already positively assisted clinical decision making by estimating the risk of recurrence and the potential benefit from adjuvant chemotherapy. However, these approaches need refinement to further reduce the proportion of patients potentially exposed to unnecessary chemotherapy. Nuclear magnetic resonance (NMR) metabolomics has demonstrated to be an optimal approach for cancer research and has provided significant results in BC, in particular for prognostic and stratification purposes. In this review, we give an update on the status of NMR-based metabolomic studies for the biochemical characterization and stratification of breast cancer patients using different biospecimens (breast tissue, blood serum/plasma, and urine).Entities:
Keywords: NMR; breast cancer; chemotherapy; metabolomics; precision medicine
Year: 2021 PMID: 33925233 DOI: 10.3390/ijms22094687
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923